This Dawnrays Pharmaceutical (Holdings) Insider Increased Their Holding In The Last Year

Looking at Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for Dawnrays Pharmaceutical (Holdings)

The Last 12 Months Of Insider Transactions At Dawnrays Pharmaceutical (Holdings)

The Chief Executive Officer Weixian Wu made the biggest insider purchase in the last 12 months. That single transaction was for HK$2.6m worth of shares at a price of HK$1.31 each. That means that an insider was happy to buy shares at around the current price of HK$1.32. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Dawnrays Pharmaceutical (Holdings) insider decided to buy shares at close to current prices. Weixian Wu was the only individual insider to buy shares in the last twelve months.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Dawnrays Pharmaceutical (Holdings) is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Dawnrays Pharmaceutical (Holdings) Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 13% of Dawnrays Pharmaceutical (Holdings) shares, worth about HK$253m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Dawnrays Pharmaceutical (Holdings) Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. With high insider ownership and encouraging transactions, it seems like Dawnrays Pharmaceutical (Holdings) insiders think the business has merit. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Dawnrays Pharmaceutical (Holdings). You'd be interested to know, that we found 1 warning sign for Dawnrays Pharmaceutical (Holdings) and we suggest you have a look.

Of course Dawnrays Pharmaceutical (Holdings) may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.